EasySep™小鼠TIL（CD45）正选试剂盒
产品号 #20104_C
细胞分选缓冲液
若您需要咨询产品或有任何技术问题，请通过官方电话 400 885 9050 或邮箱 info.cn@stemcell.com 与我们联系。
总览
RoboSep™Buffer推荐用于由RoboSep™操作的EasySep™细胞分选方案。请注意，每套RoboSep™试剂盒中包含一到两瓶缓冲液。
包含
• RoboSep™ 缓冲液（产品号 #20104）
• 杜氏磷酸盐缓冲液（PBS）
• 胎牛血清（2%）
• 含EDTA（1 mM）的PBS溶液
RoboSep™ 缓冲液（5X浓缩液；产品号 #20124）
• 5X 杜氏PBS
• 胎牛血清（10%）
• 含EDTA（5 mM）的PBS溶液
种属
人，小鼠，非人灵长类，其他物种，大鼠
品牌
RoboSep
研究领域
免疫
产品说明书及文档
请在《产品说明书》中查找相关支持信息和使用说明，或浏览下方更多实验方案。
应用领域
本产品专为以下研究领域设计，适用于工作流程中的高亮阶段。探索这些工作流程，了解更多我们为各研究领域提供的其他配套产品。
相关材料与文献
技术资料 (6)
文献 (11)
Ex vivo T cell-based HIV suppression assay to evaluate HIV-specific CD8+ T-cell responses.
Nature protocols 2010 JUN
Abstract
To advance T cell-based HIV vaccine development,it is necessary to evaluate the immune correlates of a protective CD8(+) T-cell response. We have developed an assay that assesses the capacity ex vivo of HIV-specific CD8(+) T cells to suppress HIV-1 infection of autologous CD4(+) T cells. This assay directly reflects the ultimate effector function of CD8(+) T cells,the elimination of infected cells,and accurately differentiates the effective CD8(+) T-cell response in spontaneous HIV controllers from ineffective responses in other patients. In this article,we describe all the steps from cell purification to assessment of viral replication by HIV-p24 ELISA and analysis,along with conditions for cell culturing,and how to choose the viral infectious dose that gives the most reliable results. We also depict the conditions of a rapid assay on the basis of flow cytometry analysis of intracellular HIV-Gag products. These procedures take 14-17 d when the p24 ELISA assay is used,or 6 d with the intracellular Gag assay.
CRISPR-Cas9 Ribonucleoprotein-Mediated Genomic Editing in Mature Primary Innate Immune Cells.
Cell reports 2020 may
Abstract
CRISPR genome engineering has become a powerful tool to functionally investigate the complex mechanisms of immune system regulation. While decades of work have aimed to genetically reprogram innate immunity,the utility of current approaches is restricted by poor knockout efficiencies or limited specificity for mature cell lineages in vivo. Here,we describe an optimized strategy for non-viral CRISPR-Cas9 ribonucleoprotein (cRNP) genomic editing of mature primary mouse innate lymphocyte cells (ILCs) and myeloid lineage cells that results in an almost complete loss of single or double target gene expression from a single electroporation. Furthermore,we describe in vivo adoptive transfer mouse models that can be utilized to screen for gene function during viral infection using cRNP-edited naive natural killer (NK) cells and bone-marrow-derived conventional dendritic cell precursors (cDCPs). This resource will enhance target gene discovery and offer a specific and simplified approach to gene editing in the mouse innate immune system.
Intradermal lipopolysaccharide challenge as an acute in vivo inflammatory model in healthy volunteers.
British journal of clinical pharmacology 2022 feb
Abstract
AIMS Whereas intravenous administration of Toll-like receptor 4 ligand lipopolysaccharide (LPS) to human volunteers is frequently used in clinical pharmacology studies,systemic use of LPS has practical limitations. We aimed to characterize the intradermal LPS response in healthy volunteers,and as such qualify the method as local inflammation model for clinical pharmacology studies. METHODS Eighteen healthy male volunteers received 2 or 4 intradermal 5 ng LPS injections and 1 saline injection on the forearms. The LPS response was evaluated by noninvasive (perfusion,skin temperature and erythema) and invasive assessments (cellular and cytokine responses) in skin biopsy and blister exudate. RESULTS LPS elicited a visible response and returned to baseline at 48??hours. Erythema,perfusion and temperature were statistically significant (P
View publication
沪公网安备31010102008431号